R. R. Niyazov

Suggest Changes
We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The article gives a definition of highly variable drugs, describes currently existing regulatory guidance and approaches to the study of bioequivalence of highly variable drugs, and formulates(More)
We compared anti-IIa activity of a heparin analogue and a reference product was carried out to confirm their biosimilarity. The experiment was based on the method of estimation of anti-IIa activity(More)
General principles of appropriate strategies for preclinical and clinical development of unfractionated and low-molecular-weight heparins and demonstration of their biosimilarity to corresponding(More)
  • 1